Revenue grew 13% to EUR 357 million in H1 2026, driven by CDMO expansion and Phoenix acquisition. Net profit more than doubled, while Okedi sales rose 27%. Heparin sales outlook improved, and strong cash flow led to a net cash position.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.